Visceral Pain - A Pipeline Analysis Report

Overview of the drug development pipeline for visceral pain

It has been observed that visceral pain is a type of nociceptive pain which results from the activation of nociceptors in thoracic, pelvic, or abdominal viscera organs. The causes of visceral pain are factors such as injured, physical pressure, or inflammation in some part of the body. The pain can be experienced in the trunk area of the body, including the abdominal part, pelvic organs, heart, and lungs, owing to inflammation. Visceral pain is experienced like a generalized squeezing or aching in the body. The symptoms of visceral pain may include aches, cramps, diffuse pain, bodily squeezing, and vomiting. The treatment of visceral is most efficiently carried out by the monotherapy approach.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for the treatment of visceral pain. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Try a FREE sample of this report now!

Pipeline analysis report on drug development for visceral pain: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of visceral pain. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Addex Therapeutics
• Anavex Life Sciences
• Arena Pharmaceuticals
• Chromocell
• Eli Lily

Therapeutic assessment of the drug development pipeline for visceral pain by route of administration

• Oral

The intravitreal route of administration (ROA) involves the delivery of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for visceral pain by therapy

• Monotherapy

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for visceral pain are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development. Monotherapy approach uses a single drug to treat a particular disorder.

Key questions answered in the report include

• What are the drug molecules in the various development stages for visceral pain?
• What are the companies that are currently involved in the development of drug molecules for visceral pain?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.